Abstract
The ADVANCE study (The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) was designed to evaluate the effect of reducing glycated hemoglobin to <= 6.5% on the incidence of severe vascular complications in a large group of patients with DM 2. type. A branch study completed in June 2007 evaluated the effect of lowering blood pressure with the perindopril / indapamide combination and showed a reduction in the risk of serious vascular complications and death regardless of baseline blood pressure.
In the second arm of the ADVANCE study, the aim was to compare the effect of standard treatment vs. intensive hyperglycaemia interventions based on gliclazide MR (controlled-release tablets) to reduce the risk of vascular complications.